Patents Assigned to Magforce AG
-
Patent number: 9962442Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.Type: GrantFiled: June 30, 2016Date of Patent: May 8, 2018Assignee: MAGFORCE AGInventors: Norbert Waldoefner, Andreas Jordan
-
Patent number: 9844680Abstract: The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumour volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and/or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.Type: GrantFiled: December 12, 2014Date of Patent: December 19, 2017Assignee: MAGFORCE AGInventors: Jacek Nadobny, Peng Liu, Jens-Thorsten Ollek, Heike C. Bender
-
Patent number: 9827312Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.Type: GrantFiled: September 9, 2015Date of Patent: November 28, 2017Assignee: MAGFORCE AGInventors: Andreas Jordan, Norbert Waldoefner, Regina Scholz
-
Patent number: 9814677Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.Type: GrantFiled: May 15, 2014Date of Patent: November 14, 2017Assignee: MAGFORCE AGInventors: Norbert Waldoefner, Kerstin Stief
-
Patent number: 9517272Abstract: The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released.Type: GrantFiled: December 16, 2010Date of Patent: December 13, 2016Assignee: MAGFORCE AGInventors: Jiang Gao, Monika Fischler, Volker A. Erdmann
-
Patent number: 9408912Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.Type: GrantFiled: August 7, 2012Date of Patent: August 9, 2016Assignee: MagForce AGInventors: Norbert Waldöfner, Andreas Jordan
-
Patent number: 9345768Abstract: The present invention relates to nanoparticles, wherein at least one therapeutically active substance is bound to said nanoparticle and wherein the separation of the at least one therapeutically active substance from the nanoparticle is caused or initiated by an alternating magnetic filed. Furthermore, the present invention relates to pharmaceutical compositions, in particular to injection solutions containing the nanoparticles as well as to the use thereof for the treatment of cancer.Type: GrantFiled: April 12, 2006Date of Patent: May 24, 2016Assignee: MAGFORCE AGInventors: Andreas Jordan, Norbert Waldoefner, Klaus Decken, Regina Scholz
-
Patent number: 8949088Abstract: The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumor volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and/or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.Type: GrantFiled: March 8, 2012Date of Patent: February 3, 2015Assignee: Magforce AGInventors: Jacek Nadobny, Peng Liu, Jens-Thorsten Ollek, Heike C. Bender
-
Publication number: 20140302154Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.Type: ApplicationFiled: May 15, 2014Publication date: October 9, 2014Applicant: MagForce AGInventors: Norbert WALDOEFNER, Kerstin STIEF
-
Patent number: 8771699Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.Type: GrantFiled: January 9, 2009Date of Patent: July 8, 2014Assignee: Magforce AGInventors: Norbert Waldoefner, Kerstin Stief
-
Patent number: 8688229Abstract: The invention relates to an alternating magnetic field application device for heating magnetic or magnetizable substances in biological tissue, in particular for thermal therapy using magnetic nanoparticles, composed of a large applicator (1) having a magnetic yoke (2) and two oppositely situated pole shoes (7, 8) on the magnetic yoke (2) which are separated by an exposure gap (13), and having two magnetic coils (9, 10), which are respectively associated with a pole shoe (7, 8), for generating a substantially homogenous alternating magnetic field (12) of a given field strength in the exposure gap (13), wherein the biological tissue to be irradiated may be brought into the exposure gap (13) as an exposure target volume.Type: GrantFiled: March 6, 2009Date of Patent: April 1, 2014Assignee: Magforce AGInventors: Peter Feucht, Volker Brüss, Andreas Jordan